Stock Scorecard
Stock Summary for Pulse Biosciences Inc (PLSE) - $14.32 as of 1/27/2026 8:31:43 PM EST
Total Score
5 out of 30
Safety Score
14 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PLSE
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PLSE
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PLSE
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PLSE
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PLSE (14 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for PLSE
Financial Details for PLSE
Company Overview |
|
|---|---|
| Ticker | PLSE |
| Company Name | Pulse Biosciences Inc |
| Country | N/A |
| Description | Pulse Biosciences, Inc. is at the forefront of bioelectrical medicine, based in Hayward, California, and renowned for its proprietary Nano-Pulse Stimulation (NPS) technology. This innovative non-invasive platform is designed to precisely target cellular mechanisms, facilitating advanced therapeutic interventions in dermatology and oncology. By addressing critical unmet medical needs with its state-of-the-art solutions, Pulse Biosciences presents a compelling growth opportunity, appealing to institutional investors seeking to support transformative advancements in healthcare. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL INSTRUMENTS & SUPPLIES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 14.32 |
| Price 4 Years Ago | 2.77 |
| Last Day Price Updated | 1/27/2026 8:31:43 PM EST |
| Last Day Volume | 100,734 |
| Average Daily Volume | 187,531 |
| 52-Week High | 25.00 |
| 52-Week Low | 12.56 |
| Last Price to 52 Week Low | 14.01% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 615.95 |
| Sector PE | 125.03 |
| 5-Year Average PE | -12.54 |
| Free Cash Flow Ratio | 10.23 |
| Industry Free Cash Flow Ratio | 45.44 |
| Sector Free Cash Flow Ratio | 27.44 |
| Current Ratio Most Recent Quarter | 10.02 |
| Total Cash Per Share | 1.40 |
| Book Value Per Share Most Recent Quarter | 1.37 |
| Price to Book Ratio | 11.03 |
| Industry Price to Book Ratio | 3.23 |
| Sector Price to Book Ratio | 7.34 |
| Price to Sales Ratio Twelve Trailing Months | 11,890.85 |
| Industry Price to Sales Ratio Twelve Trailing Months | 72.36 |
| Sector Price to Sales Ratio Twelve Trailing Months | 22.65 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 67,768,000 |
| Market Capitalization | 970,437,760 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -26.95% |
| Reported EPS 12 Trailing Months | -1.14 |
| Reported EPS Past Year | -0.82 |
| Reported EPS Prior Year | -0.90 |
| Net Income Twelve Trailing Months | -74,733,000 |
| Net Income Past Year | -53,585,000 |
| Net Income Prior Year | -42,210,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -147.06% |
| Operating Margin Twelve Trailing Months | -23,683.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 95,214,000 |
| Total Cash Past Year | 118,038,000 |
| Total Cash Prior Year | 44,365,000 |
| Net Cash Position Most Recent Quarter | 29,413,000 |
| Net Cash Position Past Year | 52,121,000 |
| Long Term Debt Past Year | 65,917,000 |
| Long Term Debt Prior Year | 65,917,000 |
| Total Debt Most Recent Quarter | 65,801,000 |
| Equity to Debt Ratio Past Year | 0.64 |
| Equity to Debt Ratio Most Recent Quarter | 0.58 |
| Total Stockholder Equity Past Year | 114,862,000 |
| Total Stockholder Equity Prior Year | 44,360,000 |
| Total Stockholder Equity Most Recent Quarter | 92,694,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -48,774,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.72 |
| Free Cash Flow Past Year | -36,468,000 |
| Free Cash Flow Prior Year | -33,162,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 1.78 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/27/2026 6:06:53 AM EST |